Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cilostazol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Cilostazol Tablets 100 mg |
| 2 | ACTIVE_COMPARATOR | Pletal® Tablets 100 mg |
| Name | Type | Description |
|---|---|---|
| Cilostazol Tablets 100 mg | DRUG | 100mg, single dose fasting |
| Pletal® Tablets 100 mg | DRUG | 100 single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the ev...
Cilostazol is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is also known as Cilostazol Tablets 100 mg. The drug is in Phase 1 clinical development, and its specific indications are currently undisclosed.
Cilostazol targets PDE3A, a phosphodiesterase enzyme. It acts as an inhibitor of PDE3A. This molecular target is associated with its mechanism of action.
Cilostazol is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the company responsible for the development of this drug asset.
Cilostazol is in Phase 1 of clinical development. It is an investigational drug and has not been approved by the FDA. The development program includes one completed Phase 1 trial.
Cilostazol has been studied in one completed Phase 1 trial, NCT00648388, titled "Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg." This trial enrolled 44 healthy volunteers in the United States and was active-controlled and randomized.